VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
VolitionRx Limited reports strong progress in Q1 2026, including advances in its Nu.Q® Vet and Nu.Q® NETs assays, along with plans to enter licensing agreements with leading diagnostic companies. A conference call is scheduled to discuss the financial results and business updates.
Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 14, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces financial…